Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors

US8591943B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Yongqi Deng · Newton, US
• Binyuan Sun · Sharon, US
• Hongbo Zeng · Westford, US
• Matthew Richards · Somerville, US
• Gerald W. Shipps, Jr. · Stoneham, US
• Cliff C. Cheng · Cambridge, US
• Yinyan Zhao · Greensboro, US
• Andrew J. McRiner · Melrose, US
• Zhaoyang Meng · Ambler, US
• Yang Nan · Nanjing, CN
• Mehul Patel · Blue Bell, US
• Iwona Wrona · Sharon, US
• Panduranga Adulla P. Reddy · Walpole, US
• Brian M. Eklov · Kalamazoo, US
• Shuyi Tang · Shanghai, CN
• Duan Liu · Arlington, US
• Amit K. Mandal · Shrewsbury, US
• Lianyun Zhao · Burlington, US
• M. Arshad Siddiqui · Newton, US

Key dates

• Filing date: Apr 8, 2010
• Grant date: Nov 26, 2013
• Expiry date: Apr 8, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides methods for inhibiting mTOR using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with mTOR using such compounds.